The "Psoriatic Arthritis - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.A notable advancement has been made within the Psoriatic Arthritis (PsA) therapeutic area, ...

With more than 300 patients in the trial, dubbed FOREMOST, 33.9% of those assigned to apremilast achieved minimal disease ...

The FDA cleared Bimzelx to treat adults with active psoriatic arthritis (PsA), active non-radiographic axial ...

The US Food and Drug Administration has approved bimekizumab -bkzx (Bimzelx; UCB) for adult patients with active psoriatic ...

USA: The results of the FOREMOST trial indicate that apremilast is effective for patients with early psoriatic arthritis (PsA ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...

One in four participants in a European wide study aimed at detecting early signs of psoriasis showed signs of possible ...

UCB (UCBJY) (UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic arthritis, ...

Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and ...

No new safety concerns and consistent safety profiles were observed for long-term risankizumab use in patients with psoriasis and PsA.

Tremfya is a prescription drug used for psoriasis and psoriatic arthritis. Find out about possible interactions with alcohol, ...

SAN FRANCISCO, CA, UNITED STATES, September 23, 2024 /EINPresswire / -- Each year, the National Psoriasis Foundation (NPF) invites the community of ...